



EIKO LIFESCIENCES LIMITED

F E E L T H E C H E M I S T R Y

Ref. No.: EIKO/BSE/2025-26/02

Date: 15th April, 2025

Corporate Services Department,
BSE Limited,
P J Towers, 1st Floor,
Dalal Street, Fort,
Mumbai - 400001.

Scrip Code: 540204

Subject: Reconciliation of Share Capital Audit Report for the quarter and year ended on 31st March, 2025

Dear Sir/Madam,

Please find enclosed the Reconciliation of Share Capital Audit Report for Equity Shares for the quarter and year ended on 31st March 2025. The report has been signed by M/s. Shravan A. Gupta & Associates, Practicing Company Secretary.

This report is submitted in compliance with Regulation 76 of the SEBI (Depositories and Participants), Regulations, 2018.

This is for your information and records.

Thanking you,

For Eiko Lifesciences Limited

CHINTAN
BHARATBHAI
DOSHI

Digitally signed by
CHINTAN
BHARATBHAI DOSHI
Date: 2025.04.15
18:03:32 +05'30'

Chintan Doshi
Company Secretary and Compliance Officer
Membership No: A 36190

Reconciliation of Share Capital Audit Report- Equity shares
for the Quarter and Year ended 31st March, 2025

[As per Regulation 76 of the SEBI (Depositories & Participants) Regulations, 2018]

To,
The Board of Directors
EIKO LIFESCIENCES LIMITED
604, Centrum, Opp. TMC Office,
Near Satkar Grande Hotel,
Wagle Estate, Thane-400604

I have examined the Register of Members, beneficiary details furnished by the Depositories and other records/ documents maintained by **EIKO LIFESCIENCES LIMITED** (hereinafter referred to as "the Company") and its Registrars and Share Transfer Agent **BIGSHARE SERVICES PVT. LTD**, for issuing this certificate, in accordance with Circular No. D&CC/ FITTC/ CIR-16/ 2002 dated December 31, 2002 issued by the Securities and Exchange Board of India.

In my opinion and to the best of my knowledge and according to the information and explanations given to me and based on such verification as considered necessary, I hereby certify as follows:

1. For the quarter ended:	March 31,2025
2. ISIN:	INE666Q01016
3. Face Value:	Rs. 10/- Per Share
4. Name of the Company:	Eiko Lifesciences Limited
5. Registered office address:	604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate Thane-400604
6. Correspondence address:	604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate Thane- 400604
7. Telephone & Fax Nos. Tel:	022-25390009 / 25438095 / 9820171270
8. Email Id:	investor.relations@eikolifesciences.com
9. Name of the Stock Exchanges where the Company's Securities are listed:	Bombay Stock Exchange

	Number of shares	% of Total Issued Capital
10. Issued Capital:	1,38,60,445	100
11. Listed Capital (Exchange wise):	1,24,49,551	89.82
(As per company records)		
12. Held in dematerialized form in N.S.D.L:	40,06,443	29
13. Held in dematerialized form in C.D.S.L:	84,39,608	60.89
14. Physical:	3,500	0.03
15. Total No. of shares (12+13+14):	1,24,49,551	89.82
16. Difference	14,10,894	10.18

16. Reason for difference, if any: Difference between (10 & 11) and (11 & 15) is:

The Company has issued partly paid Rights shares on call basis. On 17th December, 2024 the company issued Final reminder cum forfeiture notice for First and final call payment for 14,10,894 shares, out of which the call money was received on 12,71,303 shares. The company then allotted 12,71,303 on 24th January, 2025 and applied for listing. As on 31st March, 2025 listing approval for 12,71,303 shares is yet to be received. Hence the Difference.

Further for 1,39,591 shares, Company is yet to initiate process of forfeiture of shares.

17. Certifying the details of changes in share capital during the quarter under consideration as per table below:

Particulars* **	No. of shares	Applied / not applied for listing	Listed on Stock Exchange (Specify Names)	Whether intimate dto CDSL	Whether intimated to NSDL	In principal approval pending for SE (Specify names)
Partly Paid-up Rights Issue	12,71,303	Applied	BSE	No	No	No
Forfeiture	1,39,591	Not Applied	BSE	No	No	No

*** Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, any other (to specify):

18. Register of Members is updated (Yes/No):
If not, updated up to which date.

Yes

19. Reference of previous quarter with regards to excess dematerialized shares, if any: N.A.

20. Has the company resolved the matter mentioned in point no. 19 above in current quarter?
If not, reason why? N.A.

21. Mentioned the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:

Total No. of Demat requests	No. of requests	No. of shares	Reason for delay
Confirmed after 21 days	Nil	Nil	Nil
Pending for more than 21 days	Nil	Nil	Nil

Note: All the dematerialization requests are confirmed within 15 days from the date of receipt of DRF and Share Certificates.

22. Name, Telephone & Fax no. of the Company Secretary & Compliance Officer of the Company:

Name: Chintan Bharatbhai Doshi

Contact No. 022-25390009

23. Name, Telephone & Fax no. of the Secretarial Auditor of the Company:

Name: **M/s. Shravan A. Gupta & Associates**, Company Secretaries.

A-102, Surya Kiran Society, Near HDFC Bank, Opp. Jain Temple, Borivali west, Mumbai-400092

Cell No.9594541306, fax: 022-281847742

24. Appointment of common agency for share registry work, if yes, name & address:

Name: **Bigshare Services Pvt. Ltd**

Address: Pinnacle Business Park, Office No S6-2, 6th, Mahakali Caves Rd, next to Ahura Centre, Andheri East, Mumbai, 400093.

25. Any other detail that the CA/CS may like to provide (e.g. BIFR Company, delisting form SE, etc.): NIL

Shravan A. Gupta & Associates
Practicing Company Secretary



Shravan A. Gupta
ACS: 27484, CP: 9990
UDIN: A027484G000113988
Dated: 15-04-2025